(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Maarten J. van der Doelen discussing re-treatment of metastatic castration-resistant ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Danny Cortes discussing radiographic criteria to assess response to radioligand therapy. Currently, theranostics ...

This is a retrospective, observational, multicenter, longitudinal follow-up study to describe the treatment patterns received by the Spanish patients who received darolutamide in the ARAMIS study, ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing the utility of post-treatment SPECT/CT for identifying disease ...

Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session C: Renal Cell Cancer; ...

Dr. Axel Heidenreich presented the final results of the COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial. Clinical stage (CS) IIA/B seminoma accounts for only 10 ...

GU ASCO annual meeting featured a presentation by Dr. David Benjamin discussing the state of the genitourinary medical oncology workforce in the United States in 2024. There are approximately 13,400 ...

Dr. Bergerot concluded her presentation discussing the development of FKSI-23, a new bespoke health-related quality of life questionnaire for the advanced and adjuvant setting in RCC with the ...

GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu girentuximab + cabozantinib and ...